12:00 AM
 | 
Sep 29, 2008
 |  BioCentury  |  Product Development

Venturing into ophthalmic space

Venturing into ophthalmic space

Company Type Date Raised Description
Alacrity Biosciences Debt 3/5/07 $8.5 Developing compounds to treat ocular surface diseases, glaucoma and retinal disease. Lead compound is ALTY-0501, a topical formulation of doxycycline that has completed a Phase II trial.
Alimera Sciences Series C 3/18/08 $30.0 Focused on diseases that affect the back of the eye (retina). Lead compound is Iluvien, an intravitreal insert that delivers the corticosteroid fluocinolone acetonide. Iluvien is in Phase III testing to treat diabetic macular edema.
CoDa Therapeutics Series A 2/21/07 $20.0 Developing preclinical gap junction modulators to treat eye damage caused by surgery or mechanical injury, and for acute surgical wounds.
EyeCyte...

Read the full 761 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >